Stocks and Investing
Stocks and Investing
Mon, May 9, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Leithead Maintained (CC) at Hold with Increased Target to $46 on, May 9th, 2022
Michael Leithead of Barclays, Maintained "The Chemours Company" (CC) at Hold with Increased Target from $37 to $46 on, May 9th, 2022.
Michael has made no other calls on CC in the last 4 months.
There are 2 other peers that have a rating on CC. Out of the 2 peers that are also analyzing CC, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Zekauskas of "JP Morgan" Maintained at Hold with Decreased Target to $30 on, Monday, February 14th, 2022
This is the rating of the analyst that currently disagrees with Michael
- Arun Viswanathan of "RBC Capital" Maintained at Buy with Increased Target to $48 on, Wednesday, May 4th, 2022
Contributing Sources